Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80–90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B me...

Full description

Saved in:
Bibliographic Details
Published innpj vaccines Vol. 6; no. 1; p. 130
Main Authors Ruiz García, Yara, Sohn, Woo-Yun, Seib, Kate L., Taha, Muhamed-Kheir, Vázquez, Julio A., de Lemos, Ana Paula S., Vadivelu, Kumaran, Pizza, Mariagrazia, Rappuoli, Rino, Bekkat-Berkani, Rafik
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 29.10.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/250/255/1318
631/250/590/2294
Antigens
Bacterial infections
Biomedical and Life Sciences
Biomedicine
Genotype & phenotype
Gonorrhea
Immunization
Infectious Diseases
Medical Microbiology
Meningitis
Public Health
Review
Review Article
Sexually transmitted diseases
STD
Vaccine
Vaccines
Virology
Online AccessGet full text

Cover

More Information
Summary:Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80–90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae . Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-021-00388-3